Dopamine Released from TiO
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
31 May 2019
31 May 2019
Historique:
received:
02
04
2018
accepted:
26
02
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
29
8
2019
Statut:
epublish
Résumé
The motor dysfunction featured by patients aggrieved by Parkinson's disease (PD) results from the reduction of dopamine (DA) availability in the caudate nucleus (CN). Restituting CN DA levels is therefore essential to ameliorate PD motor deficits. In this regard, nanotechnology may offer solutions to restore CN DA availability. DA, however, can be rapidly oxidized into toxic compounds if made available in situ, unprotected. Then, we tested whether a semicrystalline TiO
Identifiants
pubmed: 31459884
doi: 10.1021/acsomega.8b00626
pmc: PMC6648478
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7953-7962Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
J Colloid Interface Sci. 1996 Jan 15;177(1):122-131
pubmed: 10479423
Anal Sci. 2002 Aug;18(8):931-3
pubmed: 12200843
J Am Chem Soc. 2005 Sep 14;127(36):12601-11
pubmed: 16144408
Lancet Neurol. 2006 Mar;5(3):235-45
pubmed: 16488379
Cell Transplant. 2006;15(3):239-50
pubmed: 16719059
Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R183-94
pubmed: 17911161
Neuropsychiatr Dis Treat. 2008 Feb;4(1):39-47
pubmed: 18728816
Neurochem Res. 2009 Apr;34(4):698-706
pubmed: 18770028
Int J Pharm. 2009 Dec 1;382(1-2):277-90
pubmed: 19703530
Phys Chem Chem Phys. 2011 Feb 21;13(7):2815-23
pubmed: 21152614
Br J Pharmacol. 2011 Oct;164(4):1357-91
pubmed: 21486284
J Am Chem Soc. 2011 May 25;133(20):7816-23
pubmed: 21542585
Int J Pharm. 2011 Oct 31;419(1-2):296-307
pubmed: 21821107
J Neurol Sci. 2012 Dec 15;323(1-2):113-6
pubmed: 22989613
Langmuir. 2014 Jul 29;30(29):8761-9
pubmed: 25003716
Nat Commun. 2014 Oct 31;5:5316
pubmed: 25360704
ACS Nano. 2015 May 26;9(5):4850-71
pubmed: 25825926
Neurosci Lett. 2016 Feb 2;613:66-71
pubmed: 26724369
J Neurosci Rural Pract. 2016 Jan-Mar;7(1):67-9
pubmed: 26933347
J Phys Chem A. 2016 Jul 14;120(27):5115-24
pubmed: 27082739
Neurosci Biobehav Rev. 2016 Sep;68:727-740
pubmed: 27422450
CNS Neurol Disord Drug Targets. 2016;15(10):1306-1324
pubmed: 27488421
J Neurochem. 2016 Oct;139 Suppl 1:325-337
pubmed: 27577098
J Nanobiotechnology. 2016 Oct 24;14(1):73
pubmed: 27776555
J Phys Chem B. 2017 Sep 21;121(37):8619-8625
pubmed: 28844138
J Biol Chem. 1974 Apr 25;249(8):2447-52
pubmed: 4362682
J Neurochem. 1995 Feb;64(2):919-24
pubmed: 7830086
Brain Res. 1993 Oct 29;626(1-2):167-74
pubmed: 8281427
Drug Dev Ind Pharm. 1998 Jul;24(7):671-5
pubmed: 9876513